Biocon Overview
Company Headquarters: Karnataka, India
Founded: 1978
Workforce: ~16,545
Company Working: Biocon manufactures and sells generic active pharmaceutical ingredients (APIs). It also provides a variety of branded formulations, complex biologics, and biosimilars like monoclonal antibodies (MAbs), rh-Insulin, and insulin analogues in addition to several active pharmaceutical ingredients (APIs). Additionally, the company provides contract manufacturing, medicine licensing, research, development, and the production of both small and large molecules to pharmaceutical and biotechnology organizations all over the world. In order to develop solutions that meet the various needs of patients around the world, Biocon has invested in cutting-edge technology, major research collaborations, and global manufacturing scale over the years. As an emerging international company, Biocon is meeting patients' needs in more than 100 nations with unique products. It has a production unit and an R&D facility at BioXcell in Malaysia. Furthermore, it has operations in the UK, Ireland, the US, Switzerland, Dubai, and Malaysia.
Strategy
The primary goal of Biocon is to deliver high-quality goods that enhance patient health while reducing risks to carers' well-being. It also focuses on creating and distributing APIs and formulation products in a variety of crucial therapeutic fields, such as virology, cancer, neurology, and women's health. it focuses on investing in the development of new capabilities and capacities across many departments, including R&D, manufacturing, and quality, as well as strengthening product line. Through solid regional partnerships, Biocon concentrated on growing its market share in fast-expanding emerging markets. Additionally, its strategy is in line with the global demand for greater access to premium, reasonably priced biopharmaceuticals and specialty medications for diabetes, cancer, and immunology.
